<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980990</url>
  </required_header>
  <id_info>
    <org_study_id>OA-UofS-778</org_study_id>
    <nct_id>NCT03980990</nct_id>
  </id_info>
  <brief_title>Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial</brief_title>
  <official_title>Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot randomized controlled trial aims to evaluate the feasibility for safety
      examination of continued metformin therapy in patients with type 2 diabetes (T2D) following
      invasive coronary angiography. Metformin will be continued until coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">June 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactic Acidosis</measure>
    <time_frame>48-72 hours (or 72 hours for patients with staged PCI procedures within 48 hours of randomization)</time_frame>
    <description>Lactate Level &gt;5 mmol/L and HCO3&lt;18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>48-72 hours (or 72 hours for patients with staged PCI procedures within 48 hours of randomization)</time_frame>
    <description>Rise in baseline creatinine &gt;/= 25% or 27 umol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality at hospital discharge</measure>
    <time_frame>Duration of hospital admission</time_frame>
    <description>Death in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Unstable Angina</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Metformin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Metformin Continuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Interruption</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Continuation of Metformin</description>
    <arm_group_label>Metformin Continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. On metformin therapy

          3. Angiography for ACS or elective non-ACS related indications

          4. Informed consent received

        Exclusion Criteria:

          1. Cardiogenic shock prior to randomization

          2. Cardiac arrest prior to randomization

          3. Established severe CKD (eGFR&lt;30, or on dialysis)

          4. Chronic liver disease

          5. Need for CABG within 48 hours of hospitalization

          6. Inability to follow the protocol and comply with follow-up requirements or any other
             reason that the investigator feels would place the patient at increased risk if the
             investigational therapy is initiated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Shavadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Department of Medicine, Division of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Shavadia, MD</last_name>
    <phone>3066553932</phone>
    <email>jss372@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Shavadia, MD</last_name>
      <phone>3066553932</phone>
      <email>jss372@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Jay Shavadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajan Minhas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haissam Haddad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Pearce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gudrun Caspar-Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Zhai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Calvin Wells, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Orvold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Udoka Okpalauwaekwe, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.</citation>
    <PMID>20393934</PMID>
  </reference>
  <reference>
    <citation>Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998 Jan 22;338(4):265-6.</citation>
    <PMID>9441244</PMID>
  </reference>
  <reference>
    <citation>Oktay V, Calpar Çıralı İ, Sinan ÜY, Yıldız A, Ersanlı MK. Impact of continuation of metformin prior to elective coronary angiography on acute contrast nephropathy in patients with normal or mildly impaired renal functions. Anatol J Cardiol. 2017 Nov;18(5):334-339. doi: 10.14744/AnatolJCardiol.2017.7836. Epub 2017 Oct 31.</citation>
    <PMID>29111980</PMID>
  </reference>
  <reference>
    <citation>Zeller M, Labalette-Bart M, Juliard JM, Potier L, Feldman LJ, Steg PG, Cottin Y, Roussel R. Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. Int J Cardiol. 2016 Oct 1;220:137-42. doi: 10.1016/j.ijcard.2016.06.076. Epub 2016 Jun 23.</citation>
    <PMID>27376570</PMID>
  </reference>
  <reference>
    <citation>Maznyczka A, Myat A, Gershlick A. Discontinuation of metformin in the setting of coronary angiography: clinical uncertainty amongst physicians reflecting a poor evidence base. EuroIntervention. 2012 Jan;7(9):1103-10. doi: 10.4244/EIJV7I9A175. Review.</citation>
    <PMID>21959259</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Jay Shavadia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>diabetes</keyword>
  <keyword>pci</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>unstable angina</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

